LED Medical Diagnostics Announces Public Market Development and Communications Plan for 2013
Raising Awareness of the Potential of Its Patented Technologies
(firmenpresse) - BURNABY, BRITISH COLUMBIA -- (Marketwire) -- 01/23/13 -- LED Medical Diagnostics Inc. ("LED Medical" or "the company") (TSX VENTURE: LMD), a developer of LED-based visualization technologies for the medical industry, announces its Public Market Development and Communications Plan for 2013, designed to create a global understanding of its proprietary, patented technology platforms and their significant potential.
"We've achieved major inroads into dentistry in recent years with the commercialization of our VELscope Vx Enhanced Oral Assessment System for the detection of early stage oral cancer," states LED Medical's CEO, Peter Whitehead. "We are now entering our second year of corporate development as a public company, and we have recently begun an exciting new partnership with DenMat () for the wide scale distribution of our VELscope Vx product line. During fiscal 2013, we will also be actively exploring the potential of our patented visualization technologies for additional applications in the medical industry. It is now important that we execute a communications strategy to expand the global investment market's understanding of the milestones we've reached, our ongoing initiatives and their value to the company."
To support its public market communications program for 2013, LED Medical has performed the following:
All engagements are for one year unless otherwise specified. All option grants are subject to both board and regulatory approval.
About LED Medical Diagnostics Inc.
Headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED-based visualization technologies for the medical industry. The company is publicly traded on the TSX.V under the symbol LMD.
Through its wholly-owned subsidiary, LED Dental Inc., the company manufactures the VELscope Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, visit .
Forward Looking Information
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding the Company's future plans for sponsorship or listings which maybe implied in this release. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Several factors could cause actual events or results to differ materially from those suggested by these forward-looking statements. Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2011. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
LED Medical Diagnostics Inc.
Mark Komonoski, Investor Relations
(403) 255-8483 or Toll-Free: (877) 255-8483
Cell: (403) 470-8384
Skype: mkomonoski
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 23.01.2013 - 11:10 Uhr
Sprache: Deutsch
News-ID 1189890
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
BURNABY, BRITISH COLUMBIA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 143 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"LED Medical Diagnostics Announces Public Market Development and Communications Plan for 2013
"
steht unter der journalistisch-redaktionellen Verantwortung von
LED Medical Diagnostics Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
